Barclays PLC Nuvalent, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Barclays PLC holds 68,107 shares of NUVL stock, worth $5.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

68,107

Previous 68,107 -0.0%

Holding current value

$5.17 Million

Previous $6.97 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$67.44 - $112.17 $2.75 Million - $4.57 Million	40,754 Added 148.99%	68,107 $6.97 Million
Q2 2024 Aug 14, 2024	SELL	$62.76 - $81.61 $257,127 - $334,356	-4,097 Reduced 13.03%	27,353 $2.08 Million
Q1 2024 May 15, 2024	SELL	$72.35 - $88.99 $4.1 Million - $5.04 Million	-56,655 Reduced 64.3%	31,450 $2.36 Million
Q4 2023 Feb 15, 2024	BUY	$42.42 - $80.28 $1.56 Million - $2.96 Million	36,862 Added 71.94%	88,105 $6.48 Million
Q3 2023 Nov 07, 2023	BUY	$39.12 - $49.85 $313,351 - $399,298	8,010 Added 18.53%	51,243 $2.36 Million
Q2 2023 Aug 03, 2023	BUY	$23.58 - $44.68 $276,121 - $523,202	11,710 Added 37.15%	43,233 $1.82 Million
Q1 2023 May 04, 2023	BUY	$25.42 - $33.52 $53,000 - $69,889	2,085 Added 7.08%	31,523 $822,000
Q4 2022 Feb 13, 2023	BUY	$18.46 - $36.37 $530,189 - $1.04 Million	28,721 Added 4005.72%	29,438 $877,000
Q3 2022 Nov 03, 2022	SELL	$13.55 - $19.92 $1,775 - $2,609	-131 Reduced 15.45%	717 $14,000
Q2 2022 Aug 12, 2022	SELL	$7.4 - $15.07 $15,747 - $32,068	-2,128 Reduced 71.51%	848 $11,000
Q1 2022 May 16, 2022	BUY	$11.65 - $19.57 $34,670 - $58,240	2,976 New	2,976 $41,000

Others Institutions Holding NUVL

# of Institutions

210

Shares Held

59.5M

Call Options Held

450K

Put Options Held

619K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.26B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account